Published on 25/12/2025
How to Use LOCF, MMRM, and Multiple Imputation in Clinical Trials
Handling missing data in clinical trials is a critical challenge that can significantly affect the integrity and reliability of study results. Patient dropouts, missed visits, and unrecorded outcomes are common, and how we address these gaps can influence regulatory decisions. To ensure robustness and minimize bias, biostatisticians use various imputation methods to estimate missing values based on observed data patterns.
Among the most widely used methods are Last Observation Carried Forward (LOCF), Mixed Models for Repeated Measures (MMRM), and Multiple Imputation (MI). Each technique has strengths and limitations, and their selection must align with the type of missing data—whether it’s Missing Completely at Random (MCAR), Missing at Random (MAR), or Missing Not at Random (MNAR).
This article offers a practical guide for selecting and applying imputation strategies in clinical trial analysis. It also reflects regulatory expectations from the USFDA and EMA, ensuring compliance with ICH guidelines and audit-readiness of your results.
1. Last Observation Carried Forward (LOCF)
What It Is:
LOCF replaces missing values with the last available observed value for that subject. It is simple and has historically been popular,
How It Works:
Suppose a subject completed Week 4 but missed Week 6 and 8 visits. LOCF will use their Week 4 value to fill in the missing timepoints.
Advantages:
- Simple to implement in most software (R, SAS, SPSS)
- Maintains the original sample size
- Helpful in sensitivity analyses
Limitations:
- Assumes no change after last observation (often unrealistic)
- Can underestimate variability and bias treatment effects
- Discouraged by regulators as a primary analysis method
Despite limitations, LOCF can still be included in pharma SOPs as a supplementary method during sensitivity analysis.
2. Mixed Models for Repeated Measures (MMRM)
What It Is:
MMRM uses all available observed data points and models the outcome over time. It assumes missing data are MAR and incorporates time as a fixed effect and subjects as random effects. Unlike LOCF, it doesn’t impute values explicitly but estimates them via maximum likelihood.
How It Works:
Each subject’s data trajectory contributes to the overall likelihood function. MMRM adjusts for baseline covariates and can accommodate unequally spaced visits and dropout patterns.
Advantages:
- Preferred by regulators when MAR assumption holds
- Statistically efficient and unbiased under MAR
- Handles unbalanced data without needing imputation
Limitations:
- Complex to implement and interpret
- Assumes missingness depends only on observed data
- Inappropriate for MNAR data
MMRM is frequently used in pivotal trials involving longitudinal measurements, such as HbA1c in diabetes or depression scores in CNS studies. It is a key strategy outlined in GMP documentation and SAPs for confirmatory trials.
3. Multiple Imputation (MI)
What It Is:
MI fills in missing data by creating several plausible values based on observed data patterns. These multiple datasets are analyzed separately, and results are pooled using Rubin’s rules to account for imputation uncertainty.
How It Works:
- Create multiple complete datasets using random draws from a predictive distribution
- Analyze each dataset using the same statistical model
- Combine estimates and standard errors across datasets
Advantages:
- Accounts for uncertainty and variability in imputed values
- Applicable under MAR, flexible with data types
- Recommended by EMA and FDA when LOCF or complete-case analysis is inappropriate
Limitations:
- Requires expert statistical knowledge to implement correctly
- Subject to model misspecification risks
- Computationally intensive for large datasets
MI is a robust method often included in primary or secondary analyses of stability studies and efficacy endpoints, especially when data collection spans long periods.
Comparison of Imputation Methods
| Method | Best For | Assumptions | Regulatory Acceptance |
|---|---|---|---|
| LOCF | Simple sensitivity analysis | Outcome remains constant | Limited—use with caution |
| MMRM | Longitudinal repeated measures | MAR, normally distributed residuals | Widely accepted |
| Multiple Imputation | Flexible for multiple data types | MAR, correct model specification | Strongly supported |
Regulatory Perspective
Regulators like EMA and CDSCO expect sponsors to:
- Specify primary and sensitivity imputation methods in the Statistical Analysis Plan
- Justify the choice of method based on the assumed missing data mechanism
- Conduct multiple imputation when data is MAR and analyze different patterns
- Perform sensitivity analyses to assess robustness of results
Inadequate handling of missing data can jeopardize trial approval, particularly when survival or patient-reported outcomes are endpoints.
Best Practices for Implementing Imputation
- Define your imputation strategy in the trial protocol and SAP
- Use validated software (e.g., SAS PROC MI, R mice package, SPSS missing values module)
- Avoid relying solely on LOCF for primary analyses
- Run multiple imputation diagnostics (convergence, plausibility)
- Include assumptions and imputation details in Clinical Study Reports
Conclusion
Effective handling of missing data through LOCF, MMRM, or Multiple Imputation is essential for unbiased, credible, and regulatory-compliant clinical trial results. While LOCF is simple, it carries assumptions that may not reflect real-world progression. MMRM offers model-based strength for longitudinal designs, and Multiple Imputation provides a statistically sound approach under MAR assumptions. Selection of the right method should be data-driven, pre-specified, and backed by best practices from the fields of pharma validation and biostatistics. In the ever-evolving landscape of drug development, a thoughtful imputation strategy can mean the difference between success and setback.